Respiratory Syncytial Virus Infection and Palivizumab: Are Families Receiving Accurate Information?

ABSTRACT

The aim of this study was to assess the accuracy of information provided by medical practitioners to families regarding the efficacy and limitations of prophylaxis with palivizumab for respiratory syncytial virus (RSV) infection in infants. A single-question survey was distributed to medical practitioners who described themselves as having both prescribed palivizumab for infants and discussed the effects of the drug with families. Responses were anonymous and returned immediately after reviewing the survey question. Respondents were requested to choose the answer that most closely resembled their understanding of palivizumab effects on the degree of illness and severity of RSV infection. All surveys distributed were completed and answers assessed by medical specialty. A total of 456 surveys were returned. Neonatologists and pediatricians accounted for the majority of responses. The answer that most closely reflects the medical literature, that palivizumab will decrease hospitalization but have no effect on need for mechanical intubation or mortality, was chosen only 2% of the time. Families are not receiving accurate information regarding the expected potential benefits and limitations of immunoprophylaxis with palivizumab. This is a very expensive drug with unclear cost-effectiveness. If changes are to be made to current recommendations as to use of palivizumab, families must receive informed consent that accurately reflects the literature.

KEYWORDS

Palivizumab - RSV infection - RSV survey

REFERENCES

• 1 American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn . Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV.  Pediatrics. 1998;  102 1211-1216
• 2 American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn . Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.  Pediatrics. 2003;  112(6 Pt 1) 1442-1446
• 3 American Academy of Pediatrics .Respiratory syncytial virus. In: Pickering LK Red Book: 2006 Report of the Committee on Infectious Diseases, 27th ed. Elk Grove Village, IL; American Academy of Pediatrics 2006: 560-566
• 4 McCarthy C A, Hall C B. Respiratory syncytial virus: concerns and control.  Pediatr Rev. 2003;  24 301-309
• 5 Leader S, Kohlhase K. Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000.  J Pediatr. 2003;  143(5, Suppl) S127-S132
• 6 Thompson W W, Shay D K, Weintraub E et al.. Mortality associated with influenza and respiratory syncytial virus in the United States.  JAMA. 2003;  289 179-186
• 7 Kapikian A Z, Mitchell R H, Chanock R M, Shvedoff R A, Stewart C E. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine.  Am J Epidemiol. 1969;  89 405-421
• 8 Groothuis J R, Simoes E A, Levin M J The Respiratory Syncytial Virus Immune Globulin Study Group et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children.  N Engl J Med. 1993;  329 1524-1530
• 9 The PREVENT Study Group . Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis.  Pediatrics. 1997;  99 93-99
• 10 The Impact-RSV Study Group . Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants.  Pediatrics. 1998;  102 531-537
• 11 Kamal-Bahl S, Doshi J, Campbell J. Economic analyses of respiratory syncytial virus immumoprophylaxis in high-risk infants: a systematic review.  Arch Pediatr Adolesc Med. 2002;  156 1034-1041
• 12 Elhassan N O, Sorbero M ES, Hall C B, Stevens T P, Dick A W. Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease.  Arch Pediatr Adolesc Med. 2006;  160 1070-1076
• 13 Resch B, Gusenleitner W, Nuijten M J, Lebmeier M, Wittenberg W. Cost-effectiveness of palivizumab against respiratory syncytial viral infection in high-risk children in Austria.  Clin Ther. 2008;  30 749-760
• 14 Dunfield L, Mierzwinski-Urban M. Palivizumab prophylaxis against RSV. Canadian Agency for Drugs & Technologies in Health: Technology report number 80. 2007
• 15 Reeve C A, Whitehall J S, Buettner P G et al.. Cost-effectiveness of respiratory syncytial virus prophylaxis with Palivizumab.  J Paediatr Child Health. 2006;  42 253-258
• 16 Vogel A M, Lennon D R, Broadbent R et al.. Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants.  J Paediatr Child Health. 2002;  38 550-554
• 17 Sharland M, Bedford-Russell A. Preventing respiratory syncitial virus bronchiolitis.  BMJ. 2001;  322 62-63
• 18 Embleton N D, Harkensee C, Mckean M C. Palivizumab for preterm infants. Is it worth it?.  Arch Dis Child Fetal Neonatal Ed. 2005;  90 F286-F289
• 19 Moler F W. RSV immune globulin prophylaxis: is an ounce of prevention worth a pound of cure?.  Pediatrics. 1999;  104(3 Pt 1) 559-560
• 20 Klassen T P. Economic evaluations of immumoprophylaxis in infants at high risk for respiratory syncytial virus: shedding light or creating confusion?.  Arch Pediatr Adolesc Med. 2002;  156 1180-1181